Long-term survival of patients with advanced melanoma who received ipilimumab administered at 10 mg/kg every 3 weeks for 4 doses (induction dosing)

3018 Background: Ipilimumab is a fully human monoclonal antibody directed against cytotoxic T-lymphocyte antigen-4 (CTLA-4), a critical suppressor of antitumor immune activity. Previously presented data from the phase I/II study MDX010–15 showed that ipilimumab induction dosing (10 mg/kg every 3 weeks [Q3W] X 4) resulted in an improved disease control rate (complete+ partial response [CR + PR] + stable disease [SD]) compared with other dosing regimens in patients with previously treated advanced melanoma. Disease control was durable, lasting > 6 months in most patients. This analysis describes overall survival data to date from the 10 mg/kg Q3W X 4 induction dosing cohort. Methods: Patients enrolled and treated in study MDX010–15 had unresectable stage III or IV melanoma and at least 1 measurable lesion. SD or progressive disease (PD) was allowed for study inclusion. Patients (n= 24) were treated with 10 mg/kg ipilimumab Q3W X 4 induction dosing. This group of patients was highly treatment-refractory: all...